Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
ConditionMalignant Solid Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSWOG Cancer Research Network
About this trial
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Eligibility criteria
Qualifiers
Participants must be planning to receive ICI-based therapy for a solid tumor malignancy. This therapy must be given according to Food and Drug Administration (FDA) label or National Comprehensive Cancer Network (NCCN) guidelines at Category 1 or 2A and not in the context of a clinical trial
Participants who have received prior ICI-based therapy must have completed ICI based therapy at least 180 days prior to registration
Participants must not have discontinued any prior ICI-based therapy (if applicable) because of irAE
Participants must not have received chemotherapy, biologic, or targeted-therapy within 21 days prior to registration
Disqualifiers
None
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Questionnaire Administration
Treatment groups
2,062 Participants
are divided into 1 treatment groupSponsors and collaborators
SWOG Cancer Research Network
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov